Engineered immune cells take aim at Hard-to-Treat blood cancer
NCT ID NCT07458659
First seen Apr 02, 2026 · Last updated May 24, 2026 · Updated 8 times
Summary
This early-phase study tests a personalized cell therapy (CART-BCMA) for people with multiple myeloma that has not responded to or returned after at least three prior treatments. The therapy uses a patient's own immune cells, modified to target a protein called BCMA on myeloma cells. The main goals are to check safety and find the right dose, with only 3 participants planned.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA(MM) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
King Chulalongkorn Memorial Hospital
Bangkok, Pathumwan, 10330, Thailand
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.